Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Vogenx Q3 EPS $(0.47) Misses $(0.09) Estimate
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Vogenx Appoints Ken Toombs to Board of Directors
WBB Securities Initiates Coverage On Vogenx with Speculative Buy Rating, Announces Price Target of $42
Jones Trading Initiates Coverage On Vogenx with Buy Rating, Announces Price Target of $55
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Vogenx Announces Closing of Initial Public Offering
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.